key: cord-0919669-77w6hgnh authors: Tong, Jiao; Zhu, Chenxi; Lai, Hanyu; Feng, Chunchao; Zhou, Dapeng title: Potent neutralization antibodies induced by a recombinant trimeric Spike protein vaccine candidate containing PIKA adjuvant for COVID-19 date: 2021-02-17 journal: bioRxiv DOI: 10.1101/2021.02.17.431647 sha: ffa55cf3865b09548c8753c485fe99e364a6fe5a doc_id: 919669 cord_uid: 77w6hgnh Neutralizing antibodies are critical to prevent corona virus infection. The structures of immunogens to elicit most potent neutralization antibodies are still under investigation. Here we tested the immunogenicity of the trimeric, full length Spike protein with 2 proline mutations to preserve its prefusion conformation. Recombinant trimeric Spike protein expressed by CHO cells was used with polyI:C (PIKA) adjuvant to immunize mice by 0-7-14 day schedule. The results showed that Spike-specific antibody was induced at day 21 with titer of more than 50,000 in average as measured by direct binding to Spike protein. The titer of neutralization reached more than 1000 in average when tested by a pseudo-virus system, using monoclonal antibodies (40592-MM57 and 40591-MM43) with neutralizing IC50 at 1 μg/ml as standards. Protein/peptide array showed that the antibodies induced by trimeric S protein vaccine bind similarly to natural infection with the receptor binding domain (RBD) as major immunodominant region. No linear epitopes were found in RBD, although several linear epitopes were found in C-terminal domain right after RBD, and heptad repeat regions. Our study supports the efficacy of recombinant trimeric Spike protein vaccine candidate for COVID-19, with excellent safety and readiness for storage and distribution in developing countries. It is generally accepted that effective COVID- 19 Both full-length Spike protein and engineered subunit of Spike protein containing 3 receptor binding domain have been reported as vaccine candidates (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In this study, we report a trimeric full length Spike protein containing PIKA (polyI:C) adjuvant. We chose such composition for several reasons: 1) The full length Spike protein contains more T cell epitopes that are essential for inducing viral-specific T cells; 2) The conformation of the trimeric form of Spike protein is similar to S-trimer structure in natural virions; 3) The PIKA (polyI:C) adjuvant has shown excellent safety and efficacy in rabies vaccines by 0-7-14 vaccination schedule (19) . The titer of antibody binding to Spike trimer protein was above 50,000 in average after 3 immunizations by trimeric Spike protein with polyI:C adjuvant. Using a pseudo-virus system, we determined the neutralizing titer to be higher than 1000 in average. Two monoclonal antibodies (40592-MM57 and 40591-MM43) with known neutralizing activities were used as standards for neutralization assays (with IC50 at 1 μg/ml). With same dose of adjuvant and proteins, trimeric Spike protein induced significantly higher neutralizing antibodies than monomeric Spike protein ( Figure 1 ). To understand the epitopes of antibodies induced by trimeric Spike protein vaccine, we performed protein/peptide array containing recombinant RBD, S1, and linear peptides of Spike protein (20) . Serum from mice vaccinated by trimeric Spike protein vaccine showed strongest binding to RBD, S1 subunit, and S proteins. However, 4 linear epitopes were only observed in the C-terminal domain right after RBD, and heptad repeat regions ( Figure 2 ). Few linear epitopes were found for RBD region, indicating that the observed antibody binding to RBD region are non-linear confirmational epitopes. These results are highly consistent with the epitope patterns of serum from patients with natural infection of COVID-19 (21) (22) . Our data support the hypothesis that the trimeric Spike protein induced antibody responses similar to natural virions. The recombinant trimeric Spike protein with polyI:C adjuvant induced neutralizing antibodies with the titer higher than 1000 in average. The comparison to antibody The similar antibody binding epitopes identified by protein/peptide array suggest that 5 the trimeric recombinant vaccine's confirmation is similar to Spike protein of natural virions. Noteworthy, monoclonal antibodies with neutralizing activities have been identified to recognize N-termianl domain (NTD, 24). Ma et al identified neutralizing antibodies which bind to C-terminal domain right after RBD (CTD) and fusion peptide (FP) region (21) . Structural analysis by Cryo-EM and molecular modeling indicated that heptad repeat (HR) regions are surface-exposed and serve as targets for neutralizing antibody binding (25) (26) (27) . Clearly, vaccines that can target the non-RBD region play important role in preventing the pandemic of mutant viruses with RBD mutations that escape the RBD-focused vaccines. To express the prefusion S ectodomain, a gene encoding residues 1−1208 of 2019-nCoV S (GenBank: MN908947) with proline substitutions at residues 986 and 987, a "GSAS" substitution at the furin cleavage site (residues 682-685), a C-terminal T4 fibritin trimerization motif, and an 8XHisTag was synthesized and cloned into the pcDNA3.1 vector. The plasmid was transfected to 293T cells and the recombinant S protein trimers were purified by Ni-NTA (nickel-nitrilotriacetic acid) chromatography (QIAGEN, Germany), followed by size exclusion to further purify the trimers. The To measure the Spike-specific antibody, 96-well microplate (NUNC-Immuno, Thermo, Waltham, MA) was coated by 50 μl 1 μg/ml S-trimer in PBS (pH 7.4) at 37ºC for one hour, washed five times by 0.05% tween in PBS (PBS/T) on a mini-shaker. The plates were blocked by 1% bovine serum albumin (Sigma, St Louis, MO) in PBS at 37ºC for one hour and washed by PBS/T for five times. Sera were diluted 25 times in the first well followed by five-fold serial dilution for ten times. Sera were incubated at 37 ºC with plate-bound S protein for one hour and washed with PBS/T for five times. Then goat anti-mouse IgG conjugated HRP (Southern Biotech, Birmingham, Alabama) was added with 5000 fold dilution in PBS, and incubated at 37 ºC for one hour. After washing for five times, chromogenic substrates were added and incubated for half an hour. The reaction was stopped with 7 H 2 SO 4 solution (1M). The absorbance was measured at 450 nm and the antibody titer was calculated with GraphPad Prism 7.0 (San Diego, CA). The protein/peptide array was performed as described (21) . Briefly, peptide-BSA conjugates as well as S protein, S1 protein, RBD protein, and other protein of The Extracellular domain of SARS-CoV-2 spike protein of that (GenBank: Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective 1 3 immunity and reduces immune enhancement. Vaccine CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. Front Immunol CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response. Vaccine A Universal Design of Betacoronavirus Vaccines against COVID-19 A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: Implications for vaccination and antibody therapeutics Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 The authors declare no conflict of interest.